News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Press Highlights of FY24
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
Penn Medicine and Parker Institute renew alliance to continue groundbreaking cancer immunotherapy research
The continued collaboration will support laboratory studies and clinical trials that leverage the science of cancer immunology.
Penn Medicine researchers use AI to uncover potential antibiotic compounds
This groundbreaking study, published in Cell, represents the largest antibiotic discovery effort to date, significantly accelerating the process of identification of candidate molecules.
Penn Engineering’s Professors Discuss Innovations Over Tea
Their “brewing” collaboration recently led to the development of a novel chip that uses light for vector-matrix multiplication.
Penn Researchers Study New Treatment Options for Brain Cancer Patients
A team of Penn researchers are exploring whether MRIs that measure the "temperature" of tumors could enhance treatment for glioblastoma, a deadly brain cancer.
Philadelphia Business Journal’s Innovation Sector Celebrates iECURE as PHL Inno’s 2024 Fire Awards Honoree
The Fire Awards aim to celebrate the most promising businesses and individuals driving success and innovation locally in Greater Philadelphia.
President’s Sustainability Prize Winner Shinkei Systems Aims to Upend the Fish-Harvesting Industry
The 2022 President’s Sustainability Prize winner Shinkei Systems was recognized in a recent article by Tech Crunch for its role in changing the seafood industry.
EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Ultragenyx Aims for FDA Approval for Sanfilippo Gene Therapy Based on Penn Technology
The drug relies on licensed foundational gene therapy technology created in the laboratory of Dr. James Wilson, MD, PhD.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.